Lupin Ltd

- The document does not explicitly mention any current or planned fundraising through debt or equity. - Net cash position improved significantly to INR 4,636 crores as of March 31, 2026, up from INR 310 crores a year ago. - The company focuses on strategic capital allocation to specialty assets and growth opportunities rather than raising new funds. - While cash generation is strong, the management is selectively looking for acquisition opportunities, especially in specialty segments, suggesting reliance on existing capital rather than new external fundraising. - No direct references to upcoming debt issuance or equity raises were found in the provided pages.

- Lupin is focused on strategic capital allocation primarily towards specialty assets in Developed Markets, including acquisitions like VISUfarma. - The company continues to seek assets in specialty segments such as ophthalmology, pulmonology, and rare neurology. - Post VISUfarma acquisition, there is a high flow of ophthalmology assets being evaluated. - Capital allocation aims at assets that complement Lupin's existing portfolios in India and specialty businesses. - Lupin remains cautious, deploying capital effectively based on risk-return criteria. - No explicit large future capex figures mentioned, but focus is on specialty business expansion and new product pipelines (biosimilars, injectables, respiratory). - Investment in R&D expected around 8% of sales going forward, emphasizing innovation. - Operating Working Capital stands at INR 7,132 crores (87 days), with net cash improving significantly (INR 4,636 crores).

- Lupin expects high single-digit revenue growth in FY27. - US business projected to sustain over USD 1 billion revenue in FY27 despite some erosion from competition. - Biosimilar franchise revenues anticipated to multiply significantly within the year. - The India prescription business plans 20 product launches in FY27, with a history of outperforming IPM growth by ~1.2x-1.3x. - Emerging Markets to maintain strong growth momentum (35.2% YoY last year), led by Brazil and South Africa. - Other Developed Markets set for growth through new complex product rollouts and VISUfarma acquisition expansion. - Biosimilars and specialty portfolios (including injectables and respiratory products) are key growth drivers. - Expect to launch 50+ products in the US over three years, including 4 biosimilars and 2-3 505(b)(2) products. - VISUfarma Europe's ophthalmology business expected to grow double digit, crossing USD 100 million in 2-3 years.

- Lupin expects high single-digit revenue growth in FY27, with EBITDA margins around 25%, despite competitive pressures and geopolitical uncertainties. - FY27 earnings guidance includes factoring in competition for key products like Tolvaptan and Mirabegron. - The biosimilars franchise is anticipated to multiply in revenue multiple times within the financial year, contributing meaningfully to profit. - The company projects launching 50+ products in the US over the next three years, including biosimilars and complex injectables, enhancing earnings. - R&D spend is expected to be around 8% of sales going forward, supporting innovation-driven growth. - Expansion in specialty and ophthalmology segments (e.g., through VISUfarma acquisition) aims to boost margins and profitability. - Operating efficiencies and improved product mix have led to improved gross margins and EBITDA growth, expected to continue. - Overall, Lupin aims to exceed market and internal expectations in FY27 and beyond, focusing on sustainable earnings growth.

The provided transcript does not explicitly mention the current or expected order book or pending orders for Lupin Limited. However, relevant points that may infer business outlook include: - Lupin’s US business achieved USD 1.3 billion sales in FY26 with a strong pipeline: 50+ product launches expected in the next three years including 10 first-to-files, 4 biosimilars, and 2-3 505(b)(2) products. - Multiple ongoing product launches and partnerships especially biosimilars (Pegfilgrastim, Ranibizumab, Aflibercept, Etanercept). - Expansion through acquisitions like VISUfarma and focus on specialty segments indicates a growing order pipeline. - Continued dialogue with partners on co-developing innovative products and platform utilization as a CDMO partner. - Strong growth momentum in key segments, particularly US complex generics and biosimilars, and expanding market presence in India and Europe. No specific numeric order book or pending order values were disclosed.